Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India.

Ekstrand ML, Shet A, Chandy S, Singh G, Shamsundar R, Madhavan V, Saravanan S, Heylen E, Kumarasamy N.

Int Health. 2011 Mar;3(1):27-34. doi: 10.1016/j.inhe.2010.11.003.

2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali.

Germanaud D, Derache A, Traore M, Madec Y, Toure S, Dicko F, Coulibaly H, Traore M, Sylla M, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2010 Jan;65(1):118-24. doi: 10.1093/jac/dkp412.

PMID:
19933171
4.

Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.

Bunupuradah T, Suntarattiwong P, Li A, Sirivichayakul S, Pancharoen C, Boonrak P, Puthanakit T, Kerr SJ, Ruxrungtham K, Chotpitayasunondh T, Hirschel B, Ananworanich J; HIV-NAT 013 Study Team.

Int J Infect Dis. 2010 Apr;14(4):e311-6. doi: 10.1016/j.ijid.2009.05.017. Epub 2009 Aug 21.

5.

Determinants of HIV-1 drug resistance in treatment-naïve patients and its clinical implications in an antiretroviral treatment program in Cameroon.

Zoufaly A, Jochum J, Hammerl R, Nassimi N, Raymond Y, Burchard GD, Schmiedel S, Drexler JF, Kay CN, Taka N, Awasom C, Metzner K, Jan vL, Feldt T.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19615. doi: 10.7448/IAS.17.4.19615. eCollection 2014.

6.

Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.

Boyd MA, Moore CL, Molina JM, Wood R, Madero JS, Wolff M, Ruxrungtham K, Losso M, Renjifo B, Teppler H, Kelleher AD, Amin J, Emery S, Cooper DA; SECOND-LINE study group.

Lancet HIV. 2015 Feb;2(2):e42-51. doi: 10.1016/S2352-3018(14)00061-7. Epub 2015 Jan 20.

PMID:
26424460
7.

Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.

Stürmer M, Dauer B, Moesch M, Haberl A, Mueller A, Locher L, Knecht G, Hanke N, Doerr HW, Staszewski S.

Antivir Ther. 2007;12(1):25-30.

PMID:
17503744
8.

The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.

Sproat M, Pozniak AL, Peeters M, Winters B, Hoetelmans R, Graham NM, Gazzard BG.

Antivir Ther. 2005;10(2):357-61.

PMID:
15865231
9.

High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.

Fofana DB, Soulié C, Baldé A, Lambert-Niclot S, Sylla M, Ait-Arkoub Z, Diallo F, Sangaré B, Cissé M, Maïga IA, Fourati S, Koita O, Calvez V, Marcelin AG, Maïga AI.

J Antimicrob Chemother. 2014 Sep;69(9):2531-5. doi: 10.1093/jac/dku153. Epub 2014 May 22.

PMID:
24855120
10.

Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.

de la Rosa R, Ruíz-Mateos E, Rubio A, Abad MA, Vallejo A, Rivero L, Genebat M, Sánchez-Quijano A, Lissen E, Leal M.

J Antimicrob Chemother. 2004 Jan;53(1):95-101. Epub 2003 Dec 4.

PMID:
14657091
11.

Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.

Barth RE, Aitken SC, Tempelman H, Geelen SP, van Bussel EM, Hoepelman AI, Schuurman R, Wensing AM.

Antivir Ther. 2012;17(2):377-86. doi: 10.3851/IMP2010. Epub 2011 Dec 2.

PMID:
22297391
12.

HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

Puthanakit T, Jourdain G, Hongsiriwon S, Suntarattiwong P, Chokephaibulkit K, Sirisanthana V, Kosalaraksa P, Petdachai W, Hansudewechakul R, Siangphoe U, Suwanlerk T, Ananworanich J; HIV-NAT 086Study Team.

HIV Med. 2010 Oct 1;11(9):565-72. doi: 10.1111/j.1468-1293.2010.00828.x. Epub 2010 Mar 25.

13.

HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam.

Pham QD, Huynh TK, Luong TT, Tran T, Vu TX, Truong LX.

HIV Clin Trials. 2013 Jan-Feb;14(1):34-44. doi: 10.1410/hct1401-34.

PMID:
23372113
14.

Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.

Nuesch R, Ananworanich J, Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A, Cooper D, Lange J, Phanuphak P, Ruxrungtham K.

Clin Infect Dis. 2005 Mar 1;40(5):728-34. Epub 2005 Feb 4.

PMID:
15714420
15.

Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon.

Aghokeng AF, Kouanfack C, Eymard-Duvernay S, Butel C, Edoul GE, Laurent C, Koulla-Shiro S, Delaporte E, Mpoudi-Ngole E, Peeters M.

J Int AIDS Soc. 2013 Jan 31;16:18004. doi: 10.7448/IAS.16.1.18004.

16.

Short communication: east meets west: a description of HIV-1 drug resistance mutation patterns of patients failing first line therapy in PEPFAR clinics from Uganda and Nigeria.

Crawford KW, Wakabi S, Kibuuka H, Magala F, Keshinro B, Okoye I, Akintunde E, Hamm TE.

AIDS Res Hum Retroviruses. 2014 Aug;30(8):796-9. doi: 10.1089/AID.2013.0294. Epub 2014 Jun 6.

PMID:
24798614
17.

Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort.

Zolfo M, Schapiro JM, Phan V, Koole O, Thai S, Vekemans M, Fransen K, Lynen L.

AIDS Res Hum Retroviruses. 2011 Jul;27(7):727-35. doi: 10.1089/AID.2010.0037. Epub 2010 Nov 23.

PMID:
20854169
18.

Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: a cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic.

Charpentier C, Gody JC, Mbitikon O, Moussa S, Matta M, Péré H, Fournier J, Longo Jde D, Bélec L.

AIDS Res Hum Retroviruses. 2012 Jan;28(1):87-94. doi: 10.1089/AID.2011.0035. Epub 2011 Jun 20.

PMID:
21599597
19.

High rates of adherence and treatment success in a public and public-private HIV clinic in India: potential benefits of standardized national care delivery systems.

Shet A, DeCosta A, Heylen E, Shastri S, Chandy S, Ekstrand M.

BMC Health Serv Res. 2011 Oct 17;11:277. doi: 10.1186/1472-6963-11-277.

20.

Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.

Røge BT, Barfod TS, Kirk O, Katzenstein TL, Obel N, Nielsen H, Pedersen C, Mathiesen LR, Lundgren JD, Gerstoft J.

HIV Med. 2004 Sep;5(5):344-51.

Supplemental Content

Support Center